Microbiological etiology of community acquired pneumonia in immunocompromised adults. - CAP-Extra

niversitair Medisch Centrum Utrecht0 个研究点目标入组 1,400 人开始时间: 待定最近更新: 2024年5月6日

适应症

试验速览

暂无简介。

•For the 1000 CAP patients:
•Immunocompromised patients, aged 18 years or older with suspicion of CAP defined as the presence of at least two of the following symptoms: fever/ hypothermia, cough, sputum production, dyspnea/ tachypnea/ hypoxia, percussion/ auscultatory findings consistent with pneumonia, leucocytosis/ leukopenia/ left shift or new infiltrate on chest X-ray. ;For the 400 controls:
•Adults (18 years or older) with an immune-compromising condition, and able to provide urine.

•For the 1000 CAP patients:
•- Patients with recent hospitalization (<2 weeks)/ residing in long-term care facilities.
•- CAPiTA participants.;For the 400 controls:
•- Subjects with suspicion of CAP or other respiratory infectious diseases, as well as evidence of or documented concomitant infectious disease within 14 days of the day of inclusion.
•- Subjects with fever (measured temperature of *38.0°C measured by a healthcare provider).
•- Subjects residing in any long-term care facilities (for example, nursing homes, respite care facilities, etc.).
•- Subjects with either pneumococcal conjugate vaccine (PCV) and/or pneumococcal polysaccharide vaccine (PPV) administration within the past 30 days.

发起方

niversitair Medisch Centrum Utrecht